Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas.

PURPOSE Differential cDNA library screening was performed on 7 human lung adenocarcinomas and 7 human lung squamous cell carcinomas and their corresponding adjacent normal tissues using a human lung cDNA library constructed from the normal bronchoalveolar cells of a 72-year-old male smoker. EXPERIMENTAL DESIGN Of the 2758 clones that were differentially expressed between normal and tumor tissues in the preliminary cDNA library screening analysis, 1163 clones were confirmed by dot blot, revealing a confirmation rate of >40%. DNA of confirmed clones was sequenced and was subjected to GenBank Blast searches. RNA expression levels were then individually analyzed by semiquantitative reverse transcription-PCR. RESULTS Ninety-two genes/sequences were differentially expressed in adenocarcinomas and/or squamous cell carcinomas compared with their corresponding normal tissues. Several genes were underexpressed by at least 50% in both tumor types such as c-fos, decorin, alpha-2-macroglobulin, platelet endothelial cell adhesion molecule 1, EGR1, and fibronectin. Ribosomal protein S3 was underexpressed only in squamous cell carcinomas, whereas expression of hepatocyte growth factor activator inhibitor type 2, ubiquitin-conjugating enzyme UBC9, and clone 333E23 on chromosome Xq21.1 were altered only in adenocarcinomas. Several genes discovered recently of which the functions are unknown, such as KIAA0728 and KIAA0425, were also differentially expressed in both adenocarcinomas and squamous cell carcinomas of the lung. CONCLUSIONS Many of these known and novel genes may be involved in human lung tumorigenesis; therefore, additional characterization is warranted and will be beneficial to the understanding of this deadly disease.

[1]  R. Beijersbergen,et al.  Cloning, expression and chromosomal localization of a new putative receptor‐like protein tyrosine phosphatase , 1991, FEBS letters.

[2]  J. Roman,et al.  Fibronectin and fibronectin receptors in lung development. , 1997, Experimental lung research.

[3]  M. Borrello,et al.  Multiple molecular alterations in mouse lung tumors , 1992, Molecular carcinogenesis.

[4]  Molecular pathogenesis of lung cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[5]  N. Nagy,et al.  Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro , 1997, Cancer Immunology, Immunotherapy.

[6]  S. Spivack,et al.  The molecular epidemiology of lung cancer. , 1997, Critical reviews in toxicology.

[7]  J. Yokota,et al.  Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display. , 1999, Genomics.

[8]  J. Yokota,et al.  How many tumor suppressor genes are involved in human lung carcinogenesis? , 1999, Carcinogenesis.

[9]  L. Isaac,et al.  Murine alpha-2-macroglobulin increase during inflammatory responses and tumor growth , 1999, Inflammation Research.

[10]  H. Hameister,et al.  Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells , 1999, Oncogene.

[11]  M. You,et al.  Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor , 2001, Oncogene.

[12]  H. Sorimachi,et al.  A Novel Ligand for CD44 Is Serglycin, a Hematopoietic Cell Lineage-specific Proteoglycan , 1995, The Journal of Biological Chemistry.

[13]  A. Bretscher,et al.  cDNA cloning and sequencing of the protein‐tyrosine kinase substrate, ezrin, reveals homology to band 4.1. , 1989, The EMBO journal.

[14]  Ruo-Pan Huang,et al.  The Transcription Factor EGR-1 Suppresses Transformation of Human Fibrosarcoma HT1080 Cells by Coordinated Induction of Transforming Growth Factor-β1, Fibronectin, and Plasminogen Activator Inhibitor-1* , 1999, The Journal of Biological Chemistry.

[15]  P. Mangeat,et al.  ERM proteins in cell adhesion and membrane dynamics. , 1999, Trends in cell biology.

[16]  W. J. Brammar,et al.  Differential expression of the mitochondrial gene cytochrome oxidase ii in benign and malignant breast tissue , 1992, The Journal of pathology.

[17]  P. Comoglio,et al.  Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. , 1996, British Journal of Cancer.

[18]  P. Newman Switched at birth: a new family for PECAM-1. , 1999, The Journal of clinical investigation.

[19]  A. Barrett,et al.  The interaction of α2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism , 1973 .

[20]  M. Fellous,et al.  Presence of an abnormal β2-microglobulin mRNA in Daudi cells: Induction by interferon , 2004, Immunogenetics.

[21]  Dietel,et al.  Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B , 2000, Histopathology.

[22]  R. Hynes,et al.  Cell surface fibronectin and oncogenic transformation. , 1979, Journal of supramolecular structure.

[23]  S. Galli,et al.  Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1 , 1996, The Journal of experimental medicine.

[24]  R. Figlin,et al.  Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. , 1995, Oncogene.

[25]  Johnson Be,et al.  The biology of lung cancer. , 1993, Seminars in oncology.

[26]  G. Nicolson,et al.  Transcripts of the mitochondrial gene ND5 are overexpressed in highly metastatic murine large cell lymphoma cells. , 1992, In vivo.

[27]  D. Mercola,et al.  Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Reiss,et al.  A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression. , 1996, Cancer research.

[29]  P. Schraml,et al.  Identification of genes differentially expressed in normal lung and non-small cell lung carcinoma tissue. , 1994, Cancer research.

[30]  Kakinuma,et al.  Expression of fibrogenic cytokines in desmoplastic malignant melanoma , 1998, The British journal of dermatology.

[31]  R. Pardi,et al.  The platelet endothelial cell adhesion molecule‐1 (PECAM1) contributes to endothelial barrier function , 1995, FEBS letters.

[32]  Y. Sibille,et al.  Local increase of antiprotease and neutrophil elastase-alpha 1-proteinase inhibitor complexes in lung cancer. , 1989, The European respiratory journal.

[33]  A. Mantovani,et al.  The origin and function of tumor-associated macrophages. , 1992, Immunology today.

[34]  R. Bravo,et al.  Monocyte chemotactic protein-3 (MCP-3)/fibroblast-induced cytokine (FIC) in eosinophilic inflammation of the airways and the inhibitory effects of an anti-MCP-3/FIC antibody. , 1997, Journal of immunology.

[35]  W. Bodmer,et al.  Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Curiel,et al.  Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. , 1994, Human gene therapy.

[37]  D. Strayer,et al.  SP‐A as a cytokine: Surfactant protein‐A–regulated transcription of surfactant proteins and other genes , 1999, Journal of cellular physiology.

[38]  N. Mifsud,et al.  Expression of Surfactant Protein mRNA in Normal and Neoplastic Lung of B6C3F1 Mice as Demonstrated by In Situ Hybridization , 1999, Veterinary pathology.

[39]  S. Tsukita,et al.  Occludin and claudins in tight-junction strands: leading or supporting players? , 1999, Trends in cell biology.

[40]  C. Garlanda,et al.  Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. , 1998, Journal of immunology.

[41]  J. Jääskeläinen,et al.  The ezrin protein family: membrane-cytoskeleton interactions and disease associations. , 1997, Current opinion in cell biology.

[42]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[43]  J. Whitsett,et al.  Expression of surfactant protein B precursor and surfactant protein B mRNA in adenocarcinoma of the lung. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[44]  S. L. Gonias,et al.  Alpha 2-macroglobulin: a protein at the interface of fibrinolysis and cellular growth regulation. , 1992, Experimental hematology.

[45]  D. Mosher,et al.  High molecular weight, cell surface-associated glycoprotein (fibronectin) lost in maglinant transformation , 1978 .

[46]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[47]  S. Hedrick Dawn of the hunt for nonclassical MHC function , 1992, Cell.

[48]  R. Ball,et al.  IMMUNOREACTIVITY FOR HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND ITS RECEPTOR, met, IN HUMAN LUNG CARCINOMAS AND MALIGNANT MESOTHELIOMAS , 1996, The Journal of pathology.

[49]  A. Bernstein,et al.  Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1 , 1996, Nature Genetics.

[50]  A. Vaheri,et al.  Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family , 1994, The Journal of cell biology.

[51]  D. Rimm,et al.  Dynamic Interaction of PTPμ with Multiple Cadherins In Vivo , 1998, The Journal of cell biology.

[52]  M. Katabami,et al.  Identification of genes that exhibit increased expression after flat reversion of NIH/3T3 cells transformed by human activated Ha-ras oncogene. , 1991, Cancer letters.

[53]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[54]  K. Takehara,et al.  Differential expression of connective tissue growth factor gene in cutaneous fibrohistiocytic and vascular tumors , 1998, Journal of cutaneous pathology.

[55]  R. Weinberg,et al.  Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. , 1989, Cancer research.

[56]  R. Weinberg Oncogenes and the molecular origins of cancer , 1989 .

[57]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[58]  A. Pardee,et al.  Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. , 1992, Science.

[59]  Adriano Fontana,et al.  The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain , 1995, Brain Research Reviews.

[60]  J. Minna,et al.  Progress in understanding the molecular pathogenesis of human lung cancer. , 1998, Biochimica et biophysica acta.

[61]  D. Bell,et al.  Advances in the analysis of chromosome alterations in human lung carcinomas. , 1997, Cancer genetics and cytogenetics.

[62]  S. Steinberg,et al.  Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. , 1992, Journal of the National Cancer Institute. Monographs.

[63]  J. Deslauriers,et al.  Carcinoma of the lung. Evaluation of satellite nodules as a factor influencing prognosis after resection. , 1989, The Journal of thoracic and cardiovascular surgery.

[64]  A. Moorman,et al.  α2‐Macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver , 1996, Hepatology.

[65]  T. Matsumura,et al.  Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. , 1999, Journal of biochemistry.

[66]  M. Weller,et al.  Transforming growth factor-β and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth , 1999, Cell and Tissue Research.

[67]  T. Tsukamoto,et al.  Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. , 1993, Cancer research.

[68]  S. Ferrone,et al.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. , 1991, The Journal of clinical investigation.

[69]  M. Takigawa,et al.  Demonstration of receptors specific for connective tissue growth factor on a human chondrocytic cell line (HCS-2/8). , 1998, Biochemical and biophysical research communications.

[70]  I. Petersen,et al.  Primary small‐cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations , 1997, International journal of cancer.

[71]  D. Mercola,et al.  Decreased Egr‐1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation , 1997, International journal of cancer.

[72]  C. Hack,et al.  Apoptosis induced by granzyme B-glycosaminoglycan complexes: implications for granule-mediated apoptosis in vivo. , 1999, Journal of immunology.

[73]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[74]  R. Whyte,et al.  Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. , 1995, British Journal of Cancer.